Effect of switching insulin treatment to exenatide based therapy in uncontrolled type 2 diabetes mellitus patients
Abstract
Purpose: In patients with uncontrolled type 2 diabetes mellitus (T2DM) on insulin therapy, increasing the insulin doses is most commonly preferred as the first choice to achieve glycaemic control. We evaluated the efficacy of initiating exenatide combination with oral antidiabetics (OAD) instead of insulin therapy.
Materials and Methods: We examined all 61 uncontrolled T2DM patients had greater than 2 ng/ml C-peptide levels and were switched from insulin and metformin therapy to exenatide combination with OAD in the period of 2015 – 2017. For examination, the patients were divided into 3 groups according to their insulin regimen as basal insulin alone, biphasic insulin and basal-bolus insulin groups. The fasting blood glucose (FBG), HbA1c and C-peptide levels of the patients were recorded before and at the 6th month of treatment.
Results: After the 6th month of the exenatide-based treatment, results show that the HbA1c levels were significantly lower than which had been evaluated before this treatment. By the end of the study, 14 of the 61 patients treated with exenatide and OAD achieved to decrease the HbA1c levels under 7.0%. FBG also decreased with the exenatide and OAD treatment.
Conclusion: We demonstrated that in order to achieve glycaemic control, exenatide-based therapy could be a better therapeutic option than increasing insulin doses with insulin and metformin treatment in patients who have uncontrolled T2DM with insulin regimens.
Keywords
Kaynakça
- 1) Chamberlain JJ, Herman WH, Leal S, Rhinehart AS, Shubrook JH, Skolnik N, et al. Pharmacologic therapy for type 2 diabetes: synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes. Annals of Internal Medicine. 2017;166(8):572-8.
- 2) Swinnen SG, Hoekstra JB, DeVries JH. Insulin therapy for type 2 diabetes. Diabetes Care. 2009;32(2):253-9.
- 3) Shaefer CF, Reid TS, Dailey G, Mabrey ME, Vlajnic A, Stuhr A, et al. Weight change in patients with type 2 diabetes starting basal insulin therapy: correlates and impact on outcomes. Postgrad Med. 2014;126:93-105.
- 4) Church TJ, Haines ST. Treatment Approach to Patients With Severe Insulin Resistance. Clin Diabetes. 2016;34:97-104.
- 5) Vora J. Combining incretin-based therapies with insulin: realizing the potential in type 2 diabetes. Diabetes Care. 2013;36:226-32.
- 6) Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. 2014;384:2228-34.
- 7) Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140-9.
- 8) Balena R, Hensley IE, Miller S, Barnett AH. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes Metab. 2013;15:485-502.
- 9) Montvida O, Klein K, Kumar S, Khunti K, Paul SK. Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients. Diabetes Obes Metab. 2017;19:108-17.
- 10) Bruinstroop E, Meyer L, Brouwer C, van Rooijen DE, van Dam PS. Retrospective Analysis of an Insulin-to-Liraglutide Switch in Patients with Type 2 Diabetes Mellitus. Diabetes Ther. 2018;9:1369-75.
